Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

Exclusive: After CureVac, Igor Splawski moves to RTW stealth startup; Lyndra’s Jessica Ballinger adds CEO title amid commercial prep

A chunky chain necklace, matching earrings, and a floral shirt with a dozen colors — that’s Igor Splawski. The former chief scientist at CureVac has

July 22, 2023

Medtronic expands AI endoscopy partnership with Cosmo

Dive Brief: Medtronic will pay Cosmo Intelligent Medical Devices $100 million upfront to expand a partnership that makes Medtronic the exclusive global distributor of Cosmo’s GI

December 11, 2023

FDA approves a clinical trial to test the effectiveness of new brain sensor array

The Federal Drug Administration approved a clinical trial to test the effectiveness of an electronic grid that records brain activity during surgery, developed by engineers

June 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.